These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19116624)

  • 1. Tetrabenazine.
    Hayden MR; Leavitt BR; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Jan; 8(1):17-8. PubMed ID: 19116624
    [No Abstract]   [Full Text] [Related]  

  • 2. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deutetrabenazine for Treatment of Chorea in Huntington Disease.
    Geschwind MD; Paras N
    JAMA; 2016 Jul; 316(1):33-5. PubMed ID: 27380339
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
    Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A
    Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine
    DeWitt SH; Maryanoff BE
    Biochemistry; 2018 Feb; 57(5):472-473. PubMed ID: 29160059
    [No Abstract]   [Full Text] [Related]  

  • 7. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.
    Frank S; Ondo W; Fahn S; Hunter C; Oakes D; Plumb S; Marshall F; Shoulson I; Eberly S; Walker F; Factor S; Hunt V; Shinaman A; Jankovic J
    Clin Neuropharmacol; 2008; 31(3):127-33. PubMed ID: 18520979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy offers HD patients relief from some symptoms. Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2.
    Morrow T
    Manag Care; 2008 Nov; 17(11):46-7. PubMed ID: 19052001
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tetrabenazine (tetrabenazine Orphan) orally].
    J Pharm Belg; 2014 Dec; (4):49-50. PubMed ID: 25562927
    [No Abstract]   [Full Text] [Related]  

  • 12. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review.
    Claassen DO; Iyer RG; Shah-Manek B; DiBonaventura M; Abler V; Sung VW
    J Huntingtons Dis; 2018; 7(4):345-353. PubMed ID: 30282372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
    ; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E
    JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine: for chorea associated with Huntington's disease.
    Scott LJ
    CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The psychopharmacology of Huntington disease.
    Petersén Å; Weydt P
    Handb Clin Neurol; 2019; 165():179-189. PubMed ID: 31727211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tetrabenazine for Huntington's disease-associated chorea.
    Poon LH; Kang GA; Lee AJ
    Ann Pharmacother; 2010 Jun; 44(6):1080-9. PubMed ID: 20442355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
    Frank S
    BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.